Following a re-submission
Erlotinib (Tarceva®) is accepted for restricted use within NHS Scotland for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, after failure of at least one prior chemotherapy regimen. When prescribing erlotinib, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effect of the treatment have been demonstrated in patients with epidermal growth factor receptor (EGFR)-negative tumours.
Erlotinib is restricted to use in patients who would otherwise be eligible for treatment with docetaxel monotherapy. No economic case has been made for those whose performance status would make them ineligible to receive docetaxel.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- Erlotinib (Tarceva®)
- SMC ID:
- 220/05
- Indication:
- Locally advanced or metastatic non small cell lung cancer after failure of at least one prior chemotherapy regimen
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Superseded
- Date advice published
- 05 June 2006